Anticarcinogenic Activity of Allylmercaptocaptopril Against Aflatoxin-B1 Induced Liver Carcinoma in Rats
More details
Hide details
SRM University, SRM College of Pharmacy, Department of Pharmacology, Kattankulathur, Kanchipuram District-603203.Tamilnadu, India
Publication date: 2011-01-11
Corresponding author
Shrinivas Sharma   

Department of Pharmacology, SRM College of Pharmacy, SRM University
Eur J Gen Med 2011;8(1):46-52
Aim: The present study was aimed to investigate the cellular and molecular mechanisms of protective effects of allylmercaptocaptopril (AMC) against liver carcinoma induced by Aflatoxin B1, a potent inducer of liver cancer. Method: In this study we determined the protective effect of AMC on liver tissue, as well as on enzymatic liver functions by estimating glycolytic enzymes like hexokinase, phosphoisomerase and aldolase, gluconeogenic enzymes like glucose-6-phosphatase and fructose 1,6 biphosphatase. Determination of total protein, DNA and RNA content also made to elucidate its action. Result: Aflatoxin B1 treatment to rats resulted in significantly elevated levels of glycolytic enzymes like hexokinase, phosphoglucoisomerase and aldolase and along with significant decrease in serum total protein, gluconeogenic enzymes and DNA and RNA content when compared to the control rats. The administration of AMC to the hepatocellular carcinoma bearing rats resulted in restoration of most of enzymatic liver functions and also total protein content, DNA and RNA content. Conclusion: Allylmercaptocaptopril has an ability to modulate the function of glycolytic and gluconeogenic enzymes, DNA and RNA synthesis in hepatocellular carcinoma which proved its anticarcinogenic activity.
Journals System - logo
Scroll to top